📊 IGC Key Takeaways
Is IGC Pharma, Inc. (IGC) a Good Investment?
IGC Pharma exhibits severe financial distress with minimal revenue ($519K), substantial operating losses ($4.8M), and negative operating cash flow ($3.5M) indicating approximately 3 months of cash runway. The company demonstrates failed or stalled commercialization with no clear path to profitability and critical going concern risk.
IGC Pharma shows minimal revenue alongside substantial operating losses and deeply negative free cash flow, indicating an early-stage commercial profile with unsustainable burn. Liquidity is tight (quick ratio below 1 and only $1.1M cash) despite very low leverage, implying reliance on external financing to fund operations. Until revenue scales materially or operating expenses decline, fundamentals point to continued losses and dilution risk.
Why Buy IGC Pharma, Inc. Stock? IGC Key Strengths
- Conservative capital structure with minimal leverage (Debt/Equity of 0.02x) providing financial flexibility
- Positive stockholders equity of $8.1M providing some balance sheet cushion
- Gross margin of 48.7% indicates reasonable unit economics if commercialization succeeds
- Very low leverage (D/E ~0.02x) and modest long-term debt
- Healthy gross margin (~49%) that could scale if revenue grows
- Asset-light model with low capex requirements
IGC Stock Risks: IGC Pharma, Inc. Investment Risks
- Critical liquidity crisis with only $1.1M cash against $3.5M quarterly burn rate signaling imminent insolvency
- Minimal revenue generation against massive operating losses indicates failed product commercialization or pre-revenue status
- Negative operating and free cash flow coupled with low cash reserves suggests bankruptcy risk without immediate capital injection
- Severe operating losses and highly negative margins/returns (ROE/ROA)
- Liquidity pressure with quick ratio <1 and limited cash versus burn
- High dependence on external financing and potential dilution
Key Metrics to Watch
- Monthly cash burn trajectory and total months of operating runway remaining
- Revenue acceleration and achievement of commercial milestones or clinical trial outcomes
- Capital raise announcements, debt restructuring activities, or strategic alternatives including merger or acquisition
- Operating cash flow (burn rate)
- Cash & equivalents
IGC Pharma, Inc. (IGC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
IGC Pharma, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IGC Profit Margin, ROE & Profitability Analysis
IGC vs Healthcare Sector: How IGC Pharma, Inc. Compares
How IGC Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IGC Pharma, Inc. Stock Overvalued? IGC Valuation Analysis 2026
Based on fundamental analysis, IGC Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IGC Pharma, Inc. Balance Sheet: IGC Debt, Cash & Liquidity
IGC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: IGC Pharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.22 indicates the company is currently unprofitable.
IGC Revenue Growth, EPS Growth & YoY Performance
IGC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $191.0K | -$1.7M | $-0.02 |
| Q1 2026 | $272.0K | -$1.6M | $-0.02 |
| Q3 2025 | $204.0K | -$1.8M | $-0.02 |
| Q2 2025 | $291.0K | -$1.7M | $-0.02 |
| Q1 2025 | $272.0K | -$2.1M | N/A |
| Q3 2024 | $204.0K | -$2.2M | N/A |
| Q2 2024 | $202.0K | -$2.4M | N/A |
| Q1 2024 | $212.0K | -$2.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IGC Pharma, Inc. Dividends, Buybacks & Capital Allocation
IGC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for IGC Pharma, Inc. (CIK: 0001326205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IGC
What is the AI rating for IGC?
IGC Pharma, Inc. (IGC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IGC's key strengths?
Claude: Conservative capital structure with minimal leverage (Debt/Equity of 0.02x) providing financial flexibility. Positive stockholders equity of $8.1M providing some balance sheet cushion. ChatGPT: Very low leverage (D/E ~0.02x) and modest long-term debt. Healthy gross margin (~49%) that could scale if revenue grows.
What are the risks of investing in IGC?
Claude: Critical liquidity crisis with only $1.1M cash against $3.5M quarterly burn rate signaling imminent insolvency. Minimal revenue generation against massive operating losses indicates failed product commercialization or pre-revenue status. ChatGPT: Severe operating losses and highly negative margins/returns (ROE/ROA). Liquidity pressure with quick ratio <1 and limited cash versus burn.
What is IGC's revenue and growth?
IGC Pharma, Inc. reported revenue of $519.0K.
Does IGC pay dividends?
IGC Pharma, Inc. does not currently pay dividends.
Where can I find IGC SEC filings?
Official SEC filings for IGC Pharma, Inc. (CIK: 0001326205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IGC's EPS?
IGC Pharma, Inc. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IGC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IGC Pharma, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IGC stock overvalued or undervalued?
Valuation metrics for IGC: ROE of -42.3% (sector avg: 15%), net margin of -659.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IGC stock in 2026?
Our dual AI analysis gives IGC Pharma, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IGC's free cash flow?
IGC Pharma, Inc.'s operating cash flow is $-3.5M, with capital expenditures of $37.0K. FCF margin is -680.9%.
How does IGC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -659.0% (avg: 12%), ROE -42.3% (avg: 15%), current ratio 1.32 (avg: 2).